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1. Introduction 
Phenylketonuria (PKU; OMIN 261600 and 261630) is an autosomal recessive genetic- 
metabolic disease. It is one of the most common of over 200 known such diseases, at least 30 
of which have treatments to ameliorate the adverse effects. PKU is one of the first diseases 
causing mental and physical disability for which successful treatment has been developed. 
The cause of PKU is defective function of the enzyme phenylanine hydroxylase (EC 
1.14.16.1) which converts phenylalanine to tyrosine. A cofactor is tetrahydrobiopterin (BH4). 
The subsequent elevation of phenylalanine in the blood and brain results in profound, 
irreversible, mental retardation in a large number of the affected individuals. The fetuses of 
nubile women with PKU are at risk as a result of the toxic effect on organ development of 
high phenylalanine levels during pregnancy (Levy & Ghavama, 1996). 
2. History 
The discovery of PKU was by Asbjorn Folling (Folling, 1934) a Norwegian 
physician/biochemist who noted that the addition of ferric chloride to the urine of 2 
retarded sibs produced a transient green coloration. He then demonstrated that this was 
caused by the phenylketone, phenylpyruvic acid, a side product of the transammination of 
phenylalanine which occurs when phenylalanine blood levels are >600 µmol/L (normal 
values 80-100 µmol/L).  He went on to test a number of retarded patients in a local 
institution and found 10 with “imbicilitas phenylpyruvica”.  Several researchers in Europe 
and North America then visited large institutions for the mentally retarded searching for 
individuals with PKU. One of whom, George Jervis (Jervis, 1937), examined 8043 “inmates” 
of 3 institutions in New York State and found 50 with PKU - most were profoundly 
retarded. Eventually it was estimated that 1-3% of mentally handicapped individuals had 
PKU. Penrose (Penrose, 1937) demonstrated the autosomal recessive nature and renamed it 
“phenylketonuria”. In 1953 it was shown that the enzyme phenylalanine hydroxylase was 
deficient (Jervis, 1953).  Successful dietary treatment with a restricted phenylalanine diet 
was reported in 1954 (Bickle et al, 1954). It became evident that much if the irreversible 
damage occurred in the first few weeks/months of life and early diagnosis was crucial. This 
led to the advent of mass newborn PKU screening (Guthrie & Susi, 1963). The majority of 
the developed world now screens newborn infants for PKU within the first few days of life. 
In 1983 the cDNA for the phenylalanine hydroxylase gene was cloned and mapped to 
chromosome 12 (12q22-q24.1) (Woo et al, 1983). To date more than 500 alleles have been 
discovered. 
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3. The biochemistry of PKU 
Phenylalanine is normally converted to tyrosine by the enzyme phenylalanine hydroxylase. 
This process is catalyzed by the cofactors tetrahydrobiopterin (BH4), O2 and iron (Figure 1).  
BH4 reduces NADP to NADPH. After oxidation to dihydropterin, NADPH regenerates 
BH4. In the absence of phenylalanine hydroxylase phenylalanine metabolism is diverted 
into a minor pathway that is not employed normally. The alanine portion of the molecule is 
transaminated to pyruvate, generating phenylpyruvate. This phenylketone spills into the 
urine; hence the name phenylketonuria (PKU). The genetics of BH4 is complicated: several 
genetically determined enzymes are involved – including dihydropteridine reductase (the 
most common to be affected), guanosine triphosphate cyclohydrolase I, 6-pyruvoy-l-
tetrahydrobiopterin synthetase, sepiapterin reductase and tetrohydropterin 2’-keto 
reductase (Matalon et al, 1989). Reduced or absent function of phenylalanine hydroxylase 
results in PKU and malfunction of the BH4 enzymes produces the biopterin deficiency 
variants. Tyrosine becomes an essential amino acid and because of the block in conversion 
of phenylalanine to tyrosine patients with PKU have low tyrosine levels (Hanley et al, 2000). 
Hence tyrosine supplementation to dietary therapy is often carried out. 
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Fig. 1. The Biochemistry of the hydroxylation of phenylalanine to tyrosine 
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4. The clinical phenotypes of PKU 
When universal newborn screening began in the 1960-70’s it was found that milder forms of 
phenylketonuria existed. Before newborn screening most of the individuals recognized as 
having PKU were those with Classical PKU (blood phenylalanine levels on an unrestricted 
diet > 1200 µmol/L). Unfortunately, there is no uniform, world-wide, agreed upon 
classification of the PKU phenotypes. There are probably a couple of dozen in the literature. 
This makes it difficult for the uninitiated.  The most widely used (Guttler, 1980) is shown in 
Table 1. 
 
Phenotype Blood phenylalanine (unrestricted diet) - µmol/L 
Classical PKU >1200
Mild/Atypical PKU 600-1200
Non-PKU mild 
hyperphenylalaninemia     (MHP) 200-600
Biopterin deficiency PKU variable
Table 1. A classification of the PKU phenotypes 
4.1 Classical PKU 
The Classical PKU phenotype (blood phenylalanine levels >1200 µmol/L on unrestricted 
diet)  usually makes up just over 50% of all cases and is responsible for the great majority of 
those profoundly retarded when untreated or late treated. This percentage varies, however, 
by jurisdiction, race and country. 
4.2 Atypical/Mild PKU 
Atypical/Mild PKU (phenylalanine levels 600-1200 µmol/L on unrestricted diet) appears to 
constitute about 20-25% of all cases. These patients suffer less severe, as a rule, intellectual 
damage if untreated. Treatment is somewhat easier since more natural protein is able to be 
administered and phenylalanine blood levels do not spike as high under metabolic stress. 
4.3 Non-PKU mild hyperphenylalaninemia (MHP) 
This phenotype makes up about 25-30% of all cases. Despite phenylalanine levels of 200-600 
µmol/L (two to six times the normal range) this variant has, in several studies, shown to be 
benign (Smith et al, 2000; Weglage et al, 2001). However, this premise has recently come 
under question (van Spronsen, 2011). The prevalence in Taiwan is 52% (Niu et al, 2010), 
double that of most jurisdictions. 
4.4 Biopterin deficiency PKU 
This variant is caused by deficient function of one of several enzymes facilitating the 
biosynthesis or regeneration of the cofactor tetrahydrobiopterin (BH4) (Matalon et al, 1989). 
Phenylalanine blood levels can vary from slightly elevated to very high. It accounts for 1-3% 
of all cases of PKU, although it may be higher in Asians – 16% in Taiwan (Niu et al, 2010). 
Since BH4 is also a cofactor in the metabolism of the amino-acids tyrosine and tryptophan, 
it’s deficiency is devastating to the infant brain (it was originally labeled as “malignant 
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PKU”). The treatment is more complicated and involves the administration, not only of 
BH4, but also L-dopa, 5-hydroxytryptophan, carbidopa and folinic acid (Matalon et al, 
1989). The majority of newborn screening programs have a protocol to detect biopterin 
deficiency in all samples testing positive for elevated phenylalanine including BH4 loading, 
analyzing blood or urinary pterins and determining blood dihydropteridine reductase 
activity (Blau et al, 2005). 
5. Genotypes of phenylalanine hydroxylase deficiency 
Over 500 alleles have been described (Scriver, 2007). In general two severe mutations result 
in severe (Classical PKU) disease, while the presence of just one mild mutation usually 
signals mild disease.  However, many exceptions arise such that the co-relation between 
phenotype and genotype is sometimes unpredictable. This has raised the question of 
modifier genes entering the equation. The majority of the defects are missense mutations but 
splice-site, nonsense and silent mutations as well as frame shifts, larger deletions and 
insertions may occur (Scriver, 2007). The phenylketonuria genotype database can be 
accessed on the internet @ www.pahdb.mcgill.ca. 
6. The worldwide prevalence of PKU and its variants 
PKU occurs worldwide but is most frequent in European Caucasians and their descendants 
– where the prevalence is about 1:10,000 births (Loeber, 2007). There is wide variation, 
however, from country to country – even in Europe. The frequency in Ireland, for example, 
is 1:4,500 (Loeber, 2007) while that in Finland is 1:100,000 to 1:200,000 (Autti-Ramo  et al, 
2005). The severe (Classical) forms occur more often in Northern and Eastern Europe (e.g. 
70% have Classical PKU in Poland (Zekanowski et al, 1997) with increasing numbers of the 
milder variants in Southern Europe (e.g. higher incidence of the milder variants in Spain 
(Desviat et al, 1999). The North American prevalence is about 1:15,000 (NIH, 2000). There is 
evidence of very high occurrence in some Middle Eastern Muslim countries related to 
consanguinity (Goldbar et al, 2002). In Israel the overall incidence is 1:11,000 with Ashkenazi 
Jews having only non-PKU mild hyperphenylalaninemia (Szeinberg et al, 1969). In Japan the 
incidence is 1:108,000 (Tada et al, 1984). It is unclear as yet what the frequency is in China 
and Taiwan. Early reports suggested an incidence of only 1:212,000 (Pangkanon et al, 2003), 
but more recently Nui (Nui  et al, 2010) report an incidence of 1:19,412 in Taiwan. Similar 
figures have been reported from China with current estimates at 1:15,000 (Zhan et al, 2009). 
The frequency is apparently low in Blacks and Aboriginals but no extensive data are 
available. 
7. Maternal PKU (MPKU) 
Maternal PKU embryopathy includes microcephaly, mental retardation, congenital heart 
disease, intrauterine growth retardation , facial dysmorphism and mid-brain defects (Levy 
& Ghavami, 1996). The clinical features are identical to those of the foetal alcohol syndrome 
(Clarren & Smith, 1978; Autti-Ramo et al, 1992) and, in fact, may be due to the same 
mechanism – interference with the activity of pyruvate dehydrogenase (Robinson, 1987; 
Hard, 2001). Numerous reviews have been published (Hanley et al, 1987) since the problem 
of MPKU was initially raised in 1963 by Mabry (Mabry et al, 1963). The most comprehensive 
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study was that of Lenke (Lenke & Levy, 1980) with a world –wide review of 524 pregnancies 
in 155 women with untreated PKU. Their findings revealed, in 172 offspring of mothers with 
Classical PKU, 92% with mental retardation, 73% with microcephaly, 12% with congenital 
heart disease and 40% with intrauterine growth retardation. Of the 120 born of mothers with 
the milder variants of PKU the foetal complications were significantly fewer. These data 
prompted the initiation of several prospective studies, one of which was the International 
(USA, Canada, Germany) Maternal PKU Collaborative Study (Koch et al, 2003), which ran 
from 1984 to 2002 and enrolled 382 women with PKU who completed 572 pregnancies. The 
outcomes demonstrated, unequivocally, the importance of good dietary control prior to 
conception or early in pregnancy (8-10 weeks) and the devastating effects of late initiation or 
poor control of diet therapy in the great majority of offspring.  
7.1 The problem of undiagnosed or lost to follow-Up females with PKU 
There is a, little recognized, problem of women with PKU, unknowingly at risk for 
producing offspring with maternal phenylketonuria embryopathy.  These women were 
born in jurisdictions where screening neonates for PKU was not yet initiated or who are 
lost to follow-up by their treatment clinics. This is compounded by the little known 
significant incidence of normal IQ in untreated PKU individuals. A recent review of the 
world literature from 1990 to 2007 (Hanley, 2008)  uncovered reports of 60 women with 
previously undiagnosed PKU, most with relatively normal intellectual function, who had 
produced 119 offspring, all profoundly damaged.  A plea was made for selective 
screening of pregnant women for PKU. A further case of maternal PKU recently 
diagnosed in a 33 year old woman in Greece only after the birth of a damaged foetus has 
been reported (Bouchlariotou et al, 2009) emphasizing that undiagnosed maternal 
phenylketonuria  remains a problem. 
8. Universal neonatal screening for PKU 
When it became obvious that early diagnosis (in the first few weeks of life) was crucial to 
successful treatment of PKU the idea of neonatal screening was introduced. It began with 
ferric chloride testing of wet diapers but numerous false negative results were discovered. 
The reason for this soon became obvious. The immature kidney of the young infant with 
PKU does not excrete phenylpyruvic acid until about 6 weeks of age. Furthermore 
phenylpyruvic acid is not produced until the blood phenylalanine level is > 600 µmol/L.  
This led to a focus on blood testing. Robert Guthrie (Guthrie & Susi, 1963), whose son was 
mentally retarded and whose niece was discovered to have PKU at age 18 months, 
developed the bacterial inhibition assay method of PKU screening. Subsequently universal, 
mass newborn screening for PKU spread to encompass many jurisdictions around the 
world. This spread has been very gradual and erratic. In many countries health care is the 
responsibility of individual states/provinces within the country. Generally, universal 
newborn PKU screening began in USA, Canada, Austrailia & New Zealand between 1963 
and 1967. In USA PKU Guthrie screening began in Oregon and Massachusetts in 1963, but 
not until 1985 in Mississippi. In Canada it began in 1965 in Nova Scotia and Ontario but not 
until 1975 in Newfoundland. In Europe PKU neonatal screening began, for the most part, 
between 1964 and 1974 but later, for example, in Poland (1976), Spain (1980-85), France 
(1964-78), NE Italy (1978), Sicily (1990), Estonia (1993), The Netherlands (1974), Czech 
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Republic (1975) (Hanley, 2008), Slovakia (1972) (Knapkova & Dluholucky, 2011), Ukraine 
(1985) (Grechanina et al, 2011).  Finland does not screen neonates for PKU (incidence 1-
100,000 to 1:,200,000 – one new case every 2-4 years) (Autti-Ramo, et al, 2005). Some other 
countries do not yet screen their neonates for PKU and in others it is incomplete. In the 
Middle East, for example, Kazakhstan began PKU screening in 2006 (Salimbaeva et al, 2011) 
and Qartar in 2003 (Ghsssan, 2011).  China (PKU incidence 1:17,000 to 1:33,000) (Jiang, 2003;  
Zao et al, 2005), began screening in 1992-1997 in Beijing, Shanghai and eight other cities but 
as of 1999 only 1.2% of neonates were screened (Gu & Chen, 1999).  
9. The treatment of PKU 
In 1954 Bickle (Bickle et al, 1953) and associates were the first to introduce treatment for 
PKU with a phenylalanine restricted diet. The first efforts were very crude and the initial 
patient was an older child already damaged. The improvement in behavior prompted more 
refined efforts. It became obvious that very early diagnosis was crucial as much of the 
adverse effect on the brain in the first few months of life were irreversible, hence the 
initiation of universal newborn screening (Guthrie & Susi, 1963). 
9.1 Restricted phenylalanine diet therapy 
The mainstay, for the past 50 years, of treatment is skillful diet manipulation by a 
metabolic dietician/nutritionist. The goal is to lower the blood/brain phenylalanine levels 
to “safe” values while still providing sufficient phenylalanine for protein formation and 
growth and to prevent catabolism. The diet is semi-synthetic, restrictive, expensive   and 
not very palatable. It includes three components: 1. “Medical Food” (formula) – a 
synthetic phenylalanine-free drink containing all the other essential amino-acids plus 
minerals, vitamins, iron and other key trace elements. 2. Natural foods – strictly “vegan-
vegetarian” (no higher protein foods such as milk, meat, fish, chicken, bread, eggs, cheese, 
nuts, certain legumes). This component of the diet provides just enough phenylalanine to 
prevent catabolism and promote growth. 3. Specially designed (expensive) low protein 
foods to give needed variety and calories to the diet. The cost of this diet is $20,000 to 
$40,000 (US) yearly. This cost is usually covered by government health plans or private 
insurance companies. One of the problems, lack of palatability, may be eased by the 
inclusion of a new modality, glycomacropeptide, in the medical food (Ney et al, 2009). 
This product is a natural protein derived from goat milk during cheese making. It is low 
in phenylalanine and high in most long chain amino acids, although tyrosine and 
tryptophan must be added. 
Target levels for blood phenylalanine are 120-360 µmol/L (Waisbren et al, 2007) and 120-240 
µmol/L for pregnancy (normal range 80-100). Recommended levels are arbitrary and 
variable but less stringent after the age of 12 years. Unfortunately there is no consistency in 
these recommendations for adolescents and adults which vary widely (Table 2) (Hanley, 
2008). Since there is no “acute metabolic/ neurological crisis” if blood levels rise (in contrast 
to some other inherited metabolic diseases) it is very common for diets to be less well 
controlled as the patients get older. In Europe and North America up to 50% of adult PKU 
patients are lost to follow-up. Of the remainder, 30-90% are “off diet”. Of those on diet, 70% 
are not in good control (Hanley, 2004a). 
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                                                 µmol/L 
 Children age 0-12 years    - 120-360 
 Adolescents and adults    - USA   <900 
                                              - UK     <700 
                                    - Germany <240 “till age 10 
                                                     <900 age 10-15 
                                                           <1200 after age 15 
                                        - France     <1200 after age 15 
 
Table 2. Recommended Guidelines for phenylalanine values in treated PKU 
The great majority of patients with PKU who were treated from early infancy, have IQ’s 
within the normal range (90-110) but are 5-15 points below their unaffected sibs and parents 
(Koch et al, 1984). In addition they often have neuropsychological (frontal lobe function) 
deficits (Welsh et al, 1990) and/or emotional/psychological/psychiatric problems (Gentile 
et al, 2010; Brumm et al, 2010). The causes of these “suboptimal” outcomes are 
multifactorial, but this has led to exploration of new, additional or alternative treatment 
modalities. 
9.1.1 Nutritional complications of dietary therapy 
Since diet therapy for PKU involves a semi—synthetic diet which may not be as bio 
available as natural foods, a number of nutritional deficiencies have emerged. Many have 
been dealt with. Vitamin B12 deficiency, for example, was found in a number of adolescents 
and young adults who were poorly compliant (Hanley et al, 1996; Robinson et al, 2000). Low 
bone density has been documented in up to 1/3 (Modan-Moses et al, 2007) of treated PKU 
patients. Long-chain fatty acid (arachidonic acid and docosahexaenoic acid (present only in 
foods from animal sources) have an important role in neurotransmission and vision. Yi (Yi 
et al, 2011) found a relationship between RBC docosahexaeonic acid and verbal ability. 
9.1.2 Portable PKU monitoring device (Biomarin Inc) 
Control of blood phenylalanine levels, especially in infants and toddlers, is critical to long 
term prevention of neurotoxic effects on the brain. The usual process is for the family to take 
heel-prick Guthrie blood spots on a regular basis and mail them in to the treatment centres. 
This involves a time span of 4-7 days to obtain results. By this time an episode that caused a 
variation in the blood levels may be over. The ideal situation would be for a home 
monitoring device to provide instant data (similar to the “Glucometer” for diabetics). 
Samples could be taken as often as daily. Regular phone consultation with the 
dietician/nutritionist would ensue. Biomarin Inc technicians are actively working on a 
prototype to move on to clinical trials. 
9.2 Pharmacological treatment 
9.2.1 Tetrahydrobiopterin (BH4, Sapropterin dihydrochloride, Kuvan®) 
The report, in 1999 (Kure et al, 1999), of several patients with phenylalanine hydroxylase 
deficiency PKU who responded to administration of BH4 with a decrease in blood 
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phenylalanine led to a virtual explosion of research and publications over the next 10 years. 
It appears that some individuals with PKU may have residual phenylalanine hydroxylase 
enzyme activity and, in this group, BH4 can act as a chemical chaperone to enhance its 
activity. Sapropterin dihydrochloride - Kuvan®, Biomarin Pharmaceutical Inc., CA, USA 
(USA & Canada), Merk Serona  SA, Geneva, Switzerland (the rest of the world) plus 
Biopten®, Japan – Asubio Pharm Co Ltd (Tokyo, Japan), is a synthetic  dihydrochloride salt 
form of the biologically active 6R-diasteroisomer of BH4 (5,6,7,8- tetrahydrobiopterin).  
Orphan drug designation and regulatory approval has been obtained in many jurisdictions. 
It comes as a soluble 100 mg oral tablet.  BH4 is also a cofactor for tyrosine hydroxylase, 
tryptophan hydroxylase, glycerine ether mono-oxydase and nitric oxide synthetase.  Thus it 
is involved in the synthesis of various neurotransmitters including adrenaline, nor-
adrenaline, dopamine, serotonin and nitrous oxide (Blau et al, 2005). “Response” to BH4 is, 
arbitrarily, set at a blood phenylalanine drop of >30% and the usual dose is 10- 20 
mg/Kg/day – with 20 mg usually favored. 
Numerous clinical trials have been carried out and more are ongoing. These include i) 
“PKU-001” (Burton et al, 2007) where  490 adolescent and adult patients (mean age 20 years) 
with “poorly controlled” PKU were studied. An 8 day course of BH4 (10 mg/Kg/day) was 
given: Ten percent of subjects with Classical PKU responded, 24% of those with 
Mild/Atypical PKU responded and 54% with MHP responded. ii) PKU-003 (Levy et al, 
2007) examined the BH4 (10 mg/kg/day) response in 89 patients previously identified as 
“responders” in the PKU-001 trial. This was a multicentre, randomized, double-blind, 
placebo-controlled 6 week trial.  Only 44% of the study subjects responded, but they showed 
a statistically significant (p<0.001), persistent, response. iii)  In a further phase III study 
(PKU-004) Lee (Lee et al, 2008) enrolled  80 patients (age >8 years) in a 22-week study 
administering BH4 doses of 5, 10 & 20 mg/Kg/day, showing  consistent response, favoring 
the 20 mg/Kg dose. iv) A study, in children age 4-12 years (PKU-006), to evaluate the ability 
of BH4 supplementation to increase the phenylalanine tolerance has been reported. This was 
a randomized, placebo controlled trial (Trefz et al, 2009).  Ninety 4-12 year old children with 
well controlled PKU were studied. They were challenged with 20mg BH4/Kg/day for 8 
days. Forty-six (51%) responded with a drop in blood phenylalanine of >30%.They showed 
a significant (p<0.001) increase tolerance for dietary phenylalanine. This enabled the 
addition of more “natural” (? bio available) protein in the diet.  More recent abstracts have 
claimed a higher incidence of BH4 “responders” using higher doses (20 mg/Kg/day) for 
longer periods (up to 1 month). For example Hennerman (Hennerman et al, 2005) reports, 
when giving a BH4 load of 20 mg/Kg to 40 neonates with a positive PKU screen, 18 (45%) 
responded. Five of these had Classical PKU and had sustained response to BH4. 
Phenylalanine tolerance increased from 18-19 mg/kg to 30-80 mg/kg “allowing substantial 
easing of dietary restrictions”.  Further studies are ongoing regarding long term safety and 
efficacy. One, in Europe, the KAMPER study (Champigneulle et al, 2009) will carry out 
regular evaluations of 625 patients in 100 European centres. Another, in USA (Kurczynski et 
al 2009), will follow 3500 patients for up to 15 years.   
Because of BH4’s multiple co-factor activity it has been postulated that it might be effective 
in treating some of the psychological/psychiatric aspects in adults. .Mosley (Mosley et al, 
2010) reports twelve, older, never treated PKU adults with “measureable maladaptive 
behavior”, treated with 20 mg/Kg/day of BH4. They found no change in blood 
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phenylalanine, an increase in blood tyrosine and “significant” improvement in behavior. 
Koch (Koch et al, 2002a) reports significant improvement of depression and panic attacks in 
a patient with mild PKU with a BH4 maintenance dose of only 100 mg/day. 
BH4, therefore, is an addition to the armamentarium of treatment options, although those 
patients needing it the most, Classical PKU, benefit the least. Patients with Atypical/Mild 
PKU would benefit the most (50-60% responders), some of whom can be managed without 
phenylalanine dietary restrictions. Up to 90% of subjects with Non-PKU mild 
hyperphenylalaninemia respond to BH4 but there is not yet good evidence to justify 
treatment in this group (Hanley, WB, 2011). The cost of BH4 is a concern. At 33-40 cents (US) 
per gram and the preferred dose of 20 mg/Kg/day, the yearly expense would range from 
$80,000 to $200,000 (child vs adult). 
9.2.2 Large neutral amino acids (LNAA) 
Large neutral amino acids (histidine, isoleucine, leucine, lysine, methionine, threonine, 
tryptophan, tyrosine, valine, and phenylalanine) compete for transport across the blood-
brain barrier via the L-type amino acid carrier. Hence, elevated plasma phenylalanine 
impairs brain uptake of the other large neutral amino acids.  Since a number of these 
depleted amino acids are precursors of certain neurotransmitters, this may be an important 
factor in brain malfunction in PKU. It is hypothesized that increased  blood levels of the 
other  large neutral amino acids might lower the phenylalanine influx and, at the same time, 
increase the brain levels of these amino acids. 
 This hypothesis has been under consideration for many years. The early experiments were 
carried out in rats (Anderson & Lawrence, 1976), where “control” pup rats were given 
phenylalanine and experimental pup rats were given phenylalanine plus large neutral 
amino acids. Both groups had similar serum levels of phenylalanine but the experimental 
group had lower brain levels. Further rat experiments were carried out (Vorhees & Berry, 
1989), where pregnant hyperphenylalaninemic rats were given supplements valine, 
isoleucine and leucine. This improved performance of their offspring in a complex maze 
test. Banos (Banos et al, 1978), in rat studies, illustrated the very rapid rate of brain amino 
acid influx in infancy which slows down in adulthood. This influx is interfered with, 
especially in infancy, if one or more of the serum amino acid levels are exceptionally high. 
Pratt (Pratt, 1982) reviewed the evidence to date and predicted that adding tyrosine or 
leucine, valine and isoleucine only, would be ineffective. Despite this, several studies in rats 
and humans claimed neurological/psychometric improvement with the administration of 
the branch chain amino acids - valine, leucine and isoleucine (Jordan, 1985; Vorhees, 1989). 
Experiments with 4 adult volunteers with PKU and 4 normal controls (Knudsen et al, 1995) 
revealed, in PKU, brain permeability to large neutral amino acids is reduced by about 50%. 
Pietz (Pietz et al, 1999) measured brain phenylalanine by magnetic resonance spectroscopy 
during an oral phenylalanine challenge. Phenylalanine influx was “completely” blocked by 
large neutral amino acid supplementation as were EEG changes. 
Since the early 90’s adult patients with PKU in Denmark have been routinely treated with 
large neutral amino acid supplements in the form of PreKUnil® (Nilab, Dk) but no 
controlled studies about efficacy have been carried out.  Three recent clinical studies have 
been published to support this approach. Koch (Koch et al, 2003a) studied 6 adult subjects 
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with PKU treated with large neutral amino acid supplementation. Blood phenylalanine 
concentrations remained unchanged but brain levels dropped. Matalon (Matalon et al, 2007) 
carried out an open label double-blind placebo control study and found a drop of 39% from 
baseline of blood phenylalanine and postulated a block of phenylalanine adsorption 
through the bowel. Schindeler (Schindeler et al, 2007) conducted a prospective, double 
blind, crossover study on 16 subjects with classical PKU. At the end of each phase brain 
phenylalanine and other metabolites were measured by magnetic resonance spectroscopy 
(MRS) plus plasma amino acids and a detailed neuropsychological assessment.  They had 
trouble with the MRS readings since they apparently had an older version of the equipment. 
A trend to lower plasma phenylalanine levels was observed as well as improvement in 
certain executive functions. They speculated that the supplements competed with 
phenylalanine at the gut level.  They concluded that large neutral amino acids had some 
beneficial effect, especially in those with high phenylalanine levels. A new large neutral 
amino acid supplement PheBLOC™ (Applied Nutrition Corp, Cedar Falls, NJ) has been 
introduced and is undergoing clinical trials. 
9.3 Enzyme  substitution therapy 
9.3.1 Phenylalanine ammonia lyase (Peg-Pal®, Biomarin Inc) 
Phenylalanine ammonia lyase, a biological (plant) enzyme, transforms phenylalanine to 
harmless metabolites, transcinnamic acid and trace ammonia. .It may lower phenylalanine 
blood levels by 30-40% or more (Sarkissian et al, 2005). The original trials were on the 
Pahenu2/enu2 mouse model (Shedlovsky et al, 1993). One of the early problems was the 
development of immunogenicity. After several rounds of treatment the effect was reduced 
by clearance of the enzyme by a neutralizing immune response.  Chemical modification 
with polyethylene glycol (PEG) has been successful in reducing this immunogenicity 
(Sarkissian, 2008). Reduction of blood and brain phenylalanine, reversal of 
hypopigmentation and continuation of good health was found after long term treatment in 
the PKU mice. The enzyme must be given subcutaneously, but once a week seems to be 
sufficient. The important advantage is that this treatment should be equally effective in all 
clinical phenotypes (most importantly Classical PKU). Clinical trials, Phase 1 and Phase 2, 
are now ongoing in eight treatment centres in the USA (Biomarin website, 2011). A 
reduction of 60% to 90% in phenylalanine blood levels have been observed with no adverse 
effect. 
9.4 Gene replacement therapy 
This approach toward long term correction of PKU has been, to the present, confined to the 
PAH enu2/enu2 PKU mouse has involved the use of a virus vector – the adeno-associated virus, 
which is non-pathogenic, minimally immunogenic and non-inflammatory (Thony, 2010). 
Liver gene therapy with this approach has had success in prolonged lowering of serum 
phenylalanine. Furthermore, the more accessible muscle, has been utilized along with 
intraperitoneal supplement with tetrahydrobiopterin, has had similar success. To date no 
human studies have been initiated. The death of one subject, due to an overwhelming 
immune reaction, when studying gene replacement in another disease, has served to temper 
this approach (Sibbald, 2001). 
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9.5 Liver cell repopulation 
Phenylalanine hydroxylase is mainly expressed in the liver. A report of a child with PKU, 
and unrelated cirrhosis, who underwent liver transplantation and was cured of his PKU 
(Varjo, 1993), led to this focus of research (Harding & Gibson, 2010). Normally functioning 
hepatocytes can be introduced to the PKU liver and, if 10-20% of the liver activity is 
provided by these cells, the disease would be cured. Various potential sources of these cells 
include healthy donors, liver or hematopoetic stem cells or embryonic stem cells. The liver is 
unique in that it can completely regenerate after injury. The problem is that, if healthy 
hepatocytes are introduced, the native hepatocytes eventually replace the donor cells unless 
there is a selective growth advantage devised for the native cells.  Successful treatment with 
this method in humans has been developed for several other diseases – notably lysosomal 
and peroxisomal storage diseases. 
10. Untreated PKU with normal intellectual function – the puzzle 
Some patients with Classical and Atypical/Mild PKU and normal intellectual function 
despite lack of treatment have been reported. The frequency of this “anomaly” is unclear. 
Textbooks continue to preach the mantra that “98%” of individuals with untreated PKU are 
profoundly mentally retarded - “normal mentality is very rare among patients with PKU 
who have not received dietary treatment” (McKusick, 1998). This persistent claim was based 
on selection biased surveys from the 1950’s to the 1970’s of institutions for the retarded 
(Paine, 1957; Partington, 1962; Pitt, 1971). They found that 1-3% of the institutional inmates 
suffered from PKU. In 1960 Eugene Knox (Knox, 1960) reviewed the available world 
literature on PKU and found reports of 466 untreated cases; 98.5% had IQ’s <60. He realized, 
however, the strong bias of ascertainment in these reports and stated that “most of the 
affected individuals have severe mental deficiency…. The few high grade cases appear to 
represent the extreme variation in this type, but the possible existence of substantial 
numbers of them in the general population has not been disproved”. Based on these early, 
pre-newborn screening, surveys it was estimated that the incidence of PKU to be 1:25,000 in 
the USA (Jervis, 1939), 1:50,000 in the UK (Munro, 1947) and 1:40,000 in Sweden (Larson, 
1954). This contrasts with the incidence of 1:10,000 to 1:15,000 revealed by newborn 
screening. The emergence of milder variants may explain some of this discrepancy. 
Underestimation because of early faulty data collection could be a factor. But there remains 
the possible existence of a significant number of normally functioning undiagnosed, 
untreated subjects with Classical and Atypical/Mild PKU, born before newborn screening. 
The epidemiologists and bioethicists continue to vehemently remind us that no statistically 
valid studies have ever been carried out on PKU newborn screening (Bodkin, 2005) or on 
PKU treatment (Rutherford et al, 2005). 
Several prospective and retrospective studies to sort this out were reported, with 
inconclusive results. Levy et al (Levy et al, 1970) screened blood samples for PKU 
(submitted for syphilis screening) from 250,000 adults in Massachusetts and found only 3 
adults with PKU – all 3 were  mentally retarded (2, in fact, were females who had produced 
4 mentally retarded offspring). Levy concluded that “among those with PKU who have not 
received dietary therapy, very few are mentally normal”. A later epidemiological review of 
this paper calculated that the “statistical power” was only 12% (Hanley, 1994). Another 
prospective study (Machill et al, 1990) screened 233,663 pregnant women for PKU between 
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1972 and 1989 and found 17 women with previously undiagnosed PKU. They concluded 
that 20% of untreated subjects with Classical PKU have normal IQ’s. This is likely high as 
some assumptions were made that appeared, to this author, not valid. However, several 
other reports support the possibility that the incidence of normal IQ in untreated PKU is 
higher than originally estimated. Berman  (Berman et al, 1969) and Koch (Koch et al, 1971) 
tested all of the unscreened older siblings of PKU neonates diagnosed in the early days of 
newborn screening and each found 15 with undiagnosed/untreated PKU; four (27%) of 
Berman’s and three (20%) of Koch’s patients had normal IQ’s. Levy (Levy et al, 1983) and 
Waisbren (Waisbren et al, 1984) tested 453,118 umbilical cord blood samples for PKU 
between 1971 and 1981 and found 22 previously undiagnosed, untreated, women with PKU. 
Of these 2 had Classical PKU, 11 had Mild/Atypical PKU and 9 had MHP. The 2 with 
Classical PKU had IQ’s of 45 & 94. Six of the 11 with Mild/Atypical PKU were available for 
testing and had a mean IQ of 97.3 (Range 78-107, SD 9.8). Six of the 9 with MHP were 
available for testing and had a mean IQ of 105.7 (Range 91-122. SD 11.8). Our review of 
published reports since 1990 on Maternal PKU (Hanley, 2008) – detailed above, suggests a 
significant population of undiagnosed PKU in the community. 
What is behind this phenotypic heterogeneity?  Proton nuclear resonance spectroscopy 
(MRS) may give some answers. Weglage (Weglage et al, 1998) describe four never treated 
adults with Classical PKU (blood levels >1200 µmol/L) – two retarded and two with normal 
IQ’s. MRS revealed high brain phenylalanine levels in the retarded and low brain 
phenylalanine levels in the normal IQ individuals. Moats (Moats et al, 2000) carried out 
MRS studies in 21 Classical PKU patients. Four of these patients who had high IQ’s despite 
having high phenylalanine levels and being off diet for at least 10 years, had low brain 
phenylalanine. In the majority of adult/adolescent patients with PKU brain phenylalanine is 
about 1/4 to 1/2 of the blood levels, but is closer to 1:1 in the neonate (Nuoffer et al, 2007).  
MRS was originally thought to detect brain phenylalanine only at blood levels of 1200 
µmol/L and above (0.0-1.5 Telsa), but new technology (7 & 10 Telsa) can measure brain 
phenylalanine if blood levels are 200 µmol/L or higher (Leuzzi et al, 2007). This technique 
has proven difficult to many researchers who have been unable to confidently reproduce the 
results of the German and Italian scientist. Bik-Mutanowski (Bik-Mutanowski & Pietrzyk, 
2007) in Poland, for example, titles his frustrations “Brain phenylalanine measurements in 
patients with PKU: serious diagnostic method or just reading tea leaves?” If this technique 
can be further refined it will likely be a mandatory step in the investigation of all patients 
with hyperphenylaninemia.  
All of this raises the possibility that “modifier genes” protect the brain of some patients with 
PKU – at least into early adulthood. The concept of modifier genes has been explored for 
some time. In foetal alcohol syndrome (FAS), for example, certain modifier genes protect the 
foetus against ethanol toxicity (Hanley et al, 2004b). 
11. Adult PKU and “Diet for Life” 
There is general agreement that PKU treatment should be lifelong (NIH, 2001) in the 
majority of patients with Classical & Mild/Atypical PKU.  As mentioned above, as the 
patients get older dietary control worsens – starting with the toddler and school child who 
can access forbidden foods when away from parental supervision to the rebellious 
adolescent and young adult. More than 250 patients with PKU per year enter adulthood in 
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North America, double that in Europe. Close to 50% of adult patients with PKU have been 
lost to follow up (Burton et al, 2010). Various reports document between 50% and 90% not 
following phenylalanine restricted diets (Koch et al, 2002b; Beasley et al, 1993; Pietz et al, 
1997) and more than 70% of those on treatment have phenylalanine levels above 
recommended values (Walter et al, 2002; Meli, 2002; Mundy, 2002). It appears that measured 
IQ does not deteriorate after age 12, even if diet therapy is absent or sub-optimal at least into 
early adulthood but, as documented above, neuropsychological, psychosocial, emotional, 
psychiatric and neurological problems arise in an unknown number. The effects in middle 
and older age groups are not yet clearly documented. The older brain in undertreated PKU 
may become more susceptible. The early patients diagnosed by newborn screening and 
treated from infancy are now just reaching their 40’s and 50’s. It is crucial to continue 
contact with this cohort. 
Deterioration of older adult PKU patients, even some never diagnosed or treated, with 
previously normal intellectual function, has been reported. Only some responded to 
introduction of therapy. Thompson (Thompson et al, 1990) documented 7 young adults, 
who had been off diet, (out of the UK cohort of 912 subjects) who developed quadriparesis, 
paraparesis, dystonia seizures, tremor and ataxia. Only two improved with dietary therapy. 
Weglage (Weglage et al, 2000) describes a 45 year old, previously undiagnosed, woman with 
an IQ of 95, who suddenly developed progressive neurological deterioration (spastic 
tetraparesis, ataxia, tremor, cognitive deterioration, disorientation, concentration problems). 
Her plasma phenylalanine was 882 µmol/L. She was placed on a low phenylalanine diet 
with good blood levels and underwent complete recovery in 6 months. A 52 year old high 
functioning successful business man in Ontario, Canada (Adams, J 2010 – personal 
communication) began having neurological symptoms and seizures. He was drinking 
copious amounts of “Diet Coke”, “Googled” aspartame and asked his neurologist to do his 
phenylalanine level – it was 4500 µ mil/L (3500 off aspartame). Kasim (Kasim et al, 2001) 
reports a woman, with an IQ of 108, functioning normally ‘till age 57, who developed slowly 
progressive spastic paraparesis and dementia. Her blood phenylalanine level was 2155 
µmol/L. She was placed on phenylalanine restricted diet with “partial improvement”. 
Ishmaru (Ishmaru et al, 1993) describes a normally functioning male who developed spastic 
paraparesis and dementia at age 32. Blood phenylalanine was 1663 µmol/L. There was no 
response to dietary therapy. 
There appears no doubt that most adult patients with PKU who are off diet therapy have 
measureable neuropsychological dysfunction (Moyie et al, 2007), which, in many cases, is 
reversible if metabolic control is reinstituted. 
The establishment of PKU centres in adult facilities, modeled after that of Lee (Lee, 2002) in 
London, UK, is urgent. If not, the success of the neonatal screening and treatment 
programmes may be blunted by the development of neuropsychological, psychosocial, 
psychiatric and neurological problems in adult patients. 
12. Conclusions 
PKU is a “success story”. It is the first example that genetic disease can be treated and 
adverse cognitive and physical disabilities prevented. This has subsequently led to 
successful treatment of a number of other genetic diseases.                 
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